![]() |
Figure 5: Ta1 improves response in difficult-to-treat hepatitis B. A randomized, controlled study comparing the responses of Ta1, IFN-alpha, and untreated historical control subjects with the difficult-to-treat HbeAg-positive hepatitis B infection show improved response (HBV DNA negative) at the end of follow-up, after treatment with Ta1 [112]. |